PubMed Health⌕ Search

Biomedical subjects

A Markiewicz

Publications and source records attributed to A Markiewicz.

86 records · Page 5Linked to original sources

The influence of anti-inflammatory drugs on the values of xylose test in man.

Anti-inflammatory drugs influence intestinal absorption. Acetylsalicylic acid, indomethacin, and PAS decrease significantly the values of xylose test in man. Paracetamol decreases the values of the test in two thirds of the subjects. Salicylamide, phenylbutazone, and sulfadimethoxine do not possess this action.

Acetaminophen↗

[Possibility of using TFX (thymus factor X) in the treatment of systemic lupus erythematosus].

A case of a 32-year female patient with the systemic lupus erythematosus is presented. The patient was treated with prednisone in a daily dose of 40-60 mg. Due to the exacerbations of the symptoms and advanced renal disorders, the patient was given TFX together with corticotherapy. Thymus factor X is an extract of real thymus of immunorecorrective properties. It specifically acts on the lymphatic system, especially disordered mechanisms of both cellular and humoral immunity. Thymus factor X was given in the dose of 10 mg (one ampoule) i.m. for the three first months followed by one ampoule every three days for the next three months. The patient is given one ampoule of TFX once a week since the 6th months of therapy. Diminishment of the symptoms was observed. The patient is in remission since a one-year follow-up period. It was also possible to reduce the dose of prednisone to 15 mg a day. The patient is controlled every 3 months. Partial normalization of renal functioning and immunological mechanisms are seen. A decrease in antinuclear antibodies and immunoglobulins, normalization in complement components, an increase in T-cells percentage and conversion of the delayed skin reaction are noted. The authors conclude that TFX may be helpful in the treatment of the autoimmunological diseases, including the systemic lupus erythematosus.

Adult↗

Seasonal variations of inflammation and ulcer incidence as assessed by upper digestive tract endoscopy.

A retrospective analysis of 3650 endoscopies shows that frequency of inflammation and ulcer incidence both in the stomach and the duodenal bulb were similar in consecutive seasons of the year. The conclusion is drawn that there may be seasonal (circannual) factors which predispose aggression to mucosa both in the stomach and duodenum, which in turn leads to seasonal occurrence of inflammation as well as to ulcer incidence.

Duodenal Diseases↗

Comparison of bioavailability of two dipyridamole formulations.

The experiment carried out on 6 volunteers shows a better bioavailability of a 75 mg single oral dose of Persantin (Boehringer) than of the same dose of Curantyl (Germed). The difference is due to the manner in which the dragées are manufactured: the bioavailability of both preparations was the same when the dragées were pulverized before oral administration.

Adult↗

Pharmacokinetic data have rhythms: are they important?

Large literature is available to support the statement that both pharmacokinetics and the susceptibility of any biosystem to drugs depend on the body's biological rhythms as well in animals as in man. There are rhythmic alterations in the drug bioavailability, metabolic processes, excretion, receptor sensitivity and pharmacologic action with peaks separated by around 24 h (i.e. circadian rhythms). In medical practice majority of the orally applicable drugs are usually administered according to the scheme "3 times daily". The arguments to administer the drug in dosi refracta are weak and validity of this formula in modern-day medicine with respect to pharmacokinetics and chronobiology will be discussed.

Asthma↗

Toward a medical prolepsis by chronobiology.

Medicine today strongly aims at prevention and optimization of diagnosis and therapy Studies tried staging and standardization of clinical trials in diseases and made search of markers for early diagnosis, prognosis and therapy. Moreover, risk factors and other variables such as predictors are now investigated more often in groups or populations of apparently healthy subjects, especially for such diseases as atherosclerosis and neoplasia. This new aspect of increasing interest may be defined as medical prolepsis (from the Greek pi rho ómicron lambda eta psi iota zeta = anticipated idea). It includes early signals of disease (protopathology) as well as other signals the host shows as defence or alarm reaction. Hence, we suggest a chronobiological approach in this field, which allows to quantify health and reveals more subtle differences in many physiological variables. According to these views, we reported studies concerning humoral markers and other parameters considered as risk factors both in atherosclerosis and in some endocrine tumors.

Arteriosclerosis↗

Circadian rhythm of intestinal absorption of xylose in man.

In sixteen volunteers, 10 g xylose tests were performed six times on different days at the following hours: 6 a.m., 10 a.m., 2 p.m., 6 p.m., 10 p.m. and 2 a.m. Xylose levels were examined in duplicate, both in blood and urine samples according to Roe and Rice. Generally, the results indicated a greater availability (i.e. absorption) of xylose in the morning than at the other times. But a circadian rhythm was detected only for two out of several examined parameters. These were: 1) blood xylose levels 90 min after ingestion time, with mesor M (mg/100 ml) = 18.8, with amplitude, A = 2.3 and with acrophase, phi = 12(22) (95% conf. limits: 7 a.m. to 4(19) p.m.), and 2) the peak of serum concentration of xylose with M = 21.2, with A = 2.2 and with phi = 11(16) a.m. (95% CL: 6(16) a.m., 5(35) p.m.).

Adult↗

Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment?

No daily rhythmicity of changes in dipyridamole (Curantyl-Germed) concentration in the blood serum of chronically treated patients receiving orally 75 mg of dipyridamole every 8 hr was found. The urinary excretion of dipyridamole was 1.37 mg/day (0.6% of the daily dose) and was significantly lower between 18.00--2.00 hr in comparison with excretion between 2.00--0.00 and 10.00-18.00.

Administration, Oral↗